HRSA-21-050: Maternal, Infant, and Early Childhood Home Visiting Program – Formula
Closed
This grant is closed. A newer notice from the same program is forecast: The Home Visiting Research, Improvement, Sustainability and Evaluation Center (HV-RISE) (HRSA-27-023). Status: Expected deadline February 23, 2027. It is in our archive of Health Resources and Services Administration notices from 2021.
Health Resources and Services Administration offered grants to the applicants described in the notice. It expected to make about 56 awards worth $342 million in total. Applications closed on June 30, 2021.
From the official notice on Grants.gov, last changed May 12, 2021. Checked November 7, 2026.
- Total funding$342 million
- Expected awards56
- Cost sharingNot required
- Funding typeGrant
Key dates
| Posted | March 18, 2021 |
|---|---|
| Deadline | June 30, 2021 |
| Archived by Grants.gov | August 14, 2021 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Eligible applicants include all states and six territories and jurisdictions serving the District of Columbia, Puerto Rico, Guam, the U.S. Virgin Islands, the Commonwealth of the Northern Mariana Islands, and American Samoa. Nonprofit organizations currently funded in FY 2020 under the MIECHV Program are also eligible to apply if the state for which they were funded to provide MIECHV services in FY 2020 does not apply.
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
This notice announces the opportunity to apply for funding under the fiscal year (FY) 2021 Maternal, Infant, and Early Childhood Home Visiting (MIECHV) Program – Formula grant. The purpose of this program is to support the delivery of coordinated and comprehensive high-quality and voluntary early childhood home visiting services to eligible families. The Health Resources and Services Administration (HRSA) administers this program in partnership with the Administration for Children and Families (ACF). Consistent with HRSA’s emphasis on innovation, collaboration, and effectiveness, the goal sat-risk communities; and (3) identify and provide comprehensive services to improve outcomes for eligible families1 of the MIECHV Program are to: (1) strengthen and improve the programs and activities carried out under Title V of the Social Security Act; (2) improve coordination of services within 2 living in at-risk communities. Successful MIECHV Program recipients will achieve the following objectives: 1) Implement evidence-based home visiting models or promising approaches that: a) Include voluntary home visiting Appendix D for definitions of evidence-based home visiting models and promising approach home visiting models for the purposes of this notice of funding opportunity (NOFO)); 3 as the primary service delivery strategy (See b) Serve eligible families residing in at-risk communities, as identified in the current approved statewide needs assessment update;4 and c) Target outcomes specified as statutorily mandated benchmark areas, which include: improved maternal and newborn health; prevention of child injuries, child abuse, neglect, or maltreatment, and reduction of emergency department visits; improvement in school readiness and achievement; reduction in crime or domestic violence; improvements in family economic self-sufficiency; and improvements in the coordination and referrals for other community resources and supports.5 2) Ensure the provision of high-quality home visiting services to eligible families living in at-risk communities by, in part, coordinating with comprehensive statewide early childhood systems to support the needs of those families. 3) Collaborate with state and local partners to increase the availability of and eligible families’ access to coordinated early childhood systems and high-quality services.
Who has won Maternal, Infant and Early Childhood Home Visiting Grant grants before
From fiscal 2021 to 2025, Maternal, Infant and Early Childhood Home Visiting Grant (93.870) awarded $2.1 billion across 410 grant awards, an average of $5.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| California Department of Public Health | California | 7 | $124 million |
| Health & Human Svc Commn TX | Texas | 3 | $82.3 million |
| PA Department of Human Services | Pennsylvania | 7 | $78.0 million |
| New Jersey Department of Health | New Jersey | 7 | $67.5 million |
| Arizona Department of Health Services | Arizona | 7 | $61.5 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, HRSA-27-023, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is HRSA-21-050 still open?
No. It closed on June 30, 2021. A newer notice is forecast: HRSA-27-023, expected deadline February 23, 2027.
Who can apply for Maternal, Infant, and Early Childhood Home Visiting Program – Formula?
Health Resources and Services Administration accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Maternal, Infant, and Early Childhood Home Visiting Program – Formula?
Closed June 30, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $342 million in total across about 56 awards.
Who has won Maternal, Infant and Early Childhood Home Visiting Grant grants before?
The largest recipients over five fiscal years were California Department of Public Health, Health & Human Svc Commn TX, PA Department of Human Services. The program made 410 awards worth $2.1 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)